{"meta":{"totalResults":6,"from":0},"results":[{"aliases":[{"type":"Abbreviation","name":"CAPE"},{"type":"USBrandName","name":"Xeloda"},{"type":"ChemicalStructureName","name":"5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine"},{"type":"CodeName","name":"Ro 09-1978/000"},{"type":"NSCNumber","name":"712807"},{"type":"CASRegistryName","name":"154361-50-9"}],"definition":{"html":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand.","text":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/capecitabine","text":"Capecitabine"},"nciConceptId":"C1794","nciConceptName":"Capecitabine","termId":42852,"name":"capecitabine","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"capecitabine"},{"aliases":[{"type":"Synonym","name":"capecitabine RDT"}],"definition":{"html":"A rapidly disintegrating film-coated tablet composed of the fluoropyrimidine carbamate antimetabolite capecitabine with antineoplastic activity. As a prodrug, capecitabine is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by hepatic carboxylesterase and then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase and is eventually activated by thymidine phosphorylase to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine triphosphate production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine rapidly disintegrating tablet (RDT) contains the water insoluble, disintegrating agent crospovidone which very rapidly disperses and swells in water making this RDT easier to swallow than the traditional capecitabine tablet.","text":"A rapidly disintegrating film-coated tablet composed of the fluoropyrimidine carbamate antimetabolite capecitabine with antineoplastic activity. As a prodrug, capecitabine is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by hepatic carboxylesterase and then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase and is eventually activated by thymidine phosphorylase to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine triphosphate production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Capecitabine rapidly disintegrating tablet (RDT) contains the water insoluble, disintegrating agent crospovidone which very rapidly disperses and swells in water making this RDT easier to swallow than the traditional capecitabine tablet."},"drugInfoSummaryLink":null,"nciConceptId":"C99629","nciConceptName":"Capecitabine Rapidly Disintegrating Tablet","termId":721986,"name":"capecitabine rapidly disintegrating tablet","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"capecitabine-rapidly-disintegrating-tablet"},{"aliases":[{"type":"Synonym","name":"Xeloda/methotrexate/navelbine regimen"},{"type":"Synonym","name":"capecitabine-methotrexate-vinorelbine regimen"},{"type":"Synonym","name":"Xeloda-methotrexate-navelbine regimen"},{"type":"Synonym","name":"XMV regimen"},{"type":"Synonym","name":"capecitabine/methotrexate/vinorelbine tartrate regimen"}],"definition":{"html":"A regimen composed of capecitabine, methotrexate and vinorelbine that can potentially be used in the treatment of breast cancer.","text":"A regimen composed of capecitabine, methotrexate and vinorelbine that can potentially be used in the treatment of breast cancer."},"drugInfoSummaryLink":null,"nciConceptId":"C134702","nciConceptName":"Capecitabine/Methotrexate/Vinorelbine Regimen","termId":789046,"name":"capecitabine/methotrexate/vinorelbine regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"capecitabine-methotrexate-vinorelbine-regimen"},{"aliases":[{"type":"Synonym","name":"CAPEOX regimen"},{"type":"Synonym","name":"capecitabine-oxaliplatin regimen"}],"definition":{"html":"A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar regimen, XELOX, with regards to the dosing schedule for oxaliplatin.","text":"A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar regimen, XELOX, with regards to the dosing schedule for oxaliplatin."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CAPOX","text":"CAPOX"},"nciConceptId":null,"nciConceptName":null,"termId":727239,"name":"CAPOX regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"capox-regimen"},{"aliases":[{"type":"Synonym","name":"capecitabine/irinotecan regimen"},{"type":"Synonym","name":"capecitabine-irinotecan regimen"},{"type":"Synonym","name":"Xeloda/Camptosar regimen"},{"type":"Synonym","name":"Xeloda-Camptosar regimen"},{"type":"Synonym","name":"Capiri"},{"type":"Synonym","name":"CAPIRI"}],"definition":{"html":"A chemotherapy regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer. ","text":"A chemotherapy regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer. "},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/XELIRI","text":"XELIRI"},"nciConceptId":"C11602","nciConceptName":"XELIRI Regimen","termId":759411,"name":"XELIRI regimen","firstLetter":"x","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"xeliri-regimen"},{"aliases":[{"type":"Synonym","name":"capecitabine-oxaliplatin regimen"},{"type":"Synonym","name":"Xeloda-oxaliplatin regimen"},{"type":"Synonym","name":"XELOX"}],"definition":{"html":"A chemotherapy regimen consisting of capecitabine (Xeloda) and oxaliplatin used for the treatment of advanced-stage colorectal cancer. This regimen differs from a similar regimen, CAPOX, with regards to the dosing schedule for oxaliplatin.","text":"A chemotherapy regimen consisting of capecitabine (Xeloda) and oxaliplatin used for the treatment of advanced-stage colorectal cancer. This regimen differs from a similar regimen, CAPOX, with regards to the dosing schedule for oxaliplatin."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/XELOX","text":"XELOX"},"nciConceptId":"C63597","nciConceptName":"XELOX Regimen","termId":657267,"name":"XELOX regimen","firstLetter":"x","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"xelox-regimen"}],"links":null}